all report title image
  • To Be Published : Oct 2022
  • Code : CMI1731
  • Industry : Biotechnology
  • Pages : N/A
  • Formats :

Adjuvant is key material that is expressed as a part of vaccine, which boost its capability to promote defense mechanism against infection. Adjuvant supports to activate immune system and permit the antigens pathogen constituents that cause an immune response in vaccines to prompt long period protective immunity. An efficient vaccine promotes both innate immunity as well as adaptive immunity, in which innate immunity is activated immediately when immune cells spots a pathogen. Successively after several days the adaptive immunity is expanded and coordinated, as immune cells called T and B cells. Adjuvants are important as they lead to immune memory which in later activate the innate immune response, subsequently leading to improved adaptive immunity with improved activation of T and B cells. According to 2015, report published by National Institute of Allergy and Infectious Disease, Alum was the only vaccine adjuvant used in U.S. till 2009, later HPV vaccine called as Cervarix was approved by Food and Drug Administration (FDA). Less immunogenicity of modern adjuvants is propelling demand for development of more efficient adjuvants in vaccines. Researchers and market players are majorly investing in R&D for development of safe and effective vaccine adjuvants, in turn boosting market growth.

Market Dynamics

Increasing prevalence of naïve infectious chronic diseases around the globe is the major factor propelling demand for more improved and long lasting vaccination. Moreover, factors such as growing support of government in research and development, high incidences of epidemic outbreaks, tactical development interchanges adopted by companies such as acquisitions, agreements, and collaborations are supporting growth of the vaccine adjuvants market. For instance, in July 2017, the U.S Food and Drug Administration (FDA) approved Nerlynx a product of Puma Biotechnology Inc. for adjuvant treatment of breast cancer. Such innovations are driving growth of the vaccine adjuvants market. However, restrains such as side effects and high toxicity of adjuvants on application, huge investment required for developing a new adjuvant and strict regulatory requirements are expected to hinder growth of vaccine adjuvants market. For instance, an article published in 2016, Scientific Reports Journal revealed the toxicity of aluminum adjuvants in clinically approved various human vaccinations.

Regional Insights

On the basis of the region, the global vaccine adjuvant market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the dominant position in market in the term of revenue, owing to high adoption of the innovative products and presence of major market players in this region especially in the U.S. Moreover, favorable government support towards the growth of healthcare infrastructure is also accelerating growth of the vaccine adjuvants market in this region. Asia Pacific region is expected to witness significant growth, owing to presence of large population prone to various chronic and infectious diseases such as HIV, influenza, hepatitis, and cancer. Therefore, introduction of innovative adjuvants vaccine may provide better solutions to the patient at the marginally lower costs. Vaccine adjuvants market is growing at significant rate, owing to development of innovative and efficient products to meet increasing demand from end users.

Competitive Insights 

The key player operating in the global vaccine adjuvant market include, SEPPIC Inc., Novavax, Inc., Hayashibara Co., Ltd., SPI Pharma Inc, Invivogen, Avanti Polar Lipids, Inc., MPV Technologies, OZ Biosciences, Agenus,Inc., Brenntag Biosector, Spectrum Pharmaceuticals. Inc., Sigma Aldrich, Adjuatis, Vaxliant, Adjuvance Technologies, Inc., GlaxoSmithKline plc., Puma Biotechnology, Tj Kaiwei, Zhouyue, Aphios, and CSL Limited. Market players are focused on providing technologically advanced products to retain leading position in the market. For instance, in 2013, Benchmark Biolabs and AgriLabs announced the establishment of VaxLiant, a joint venture designed to modernize vaccines deliver antigens to prevent diseases. Moreover, in 2013 Hayashibara Co., Ltd. developed a new effective and stable vaccine adjuvant encapsulated within nano-particles of pullulan derivatives.

Market Taxonomy

On the basis of product type, the global vaccine adjuvant market is segmented into:

  • Particulate Adjuvants
  • Emulsions Adjuvants
  • Pathogen Adjuvants
  • Combination Adjuvants
  • Others Adjuvants

On the basis of route of administration, the global vaccine adjuvant market is segmented into:

  • Oral
  • Intranasal
  • Intramuscular
  • Intradermal
  • Others

On the basis of disease type, the global vaccine adjuvant market is segmented into:

  • Cancer
  • Infectious Disease
  • Other

On the basis of application type, the global vaccine adjuvants market is segmented into:

  • Research
  • Commercial
  • Others

On the basis of region, the global vaccine adjuvants market is segmented into:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Related Reports


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo